Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Dr. Reddy's Labs has become the world's first company to launch a generic version of Amgen's erythropoiesis-stimulating agent Aranesp (darbepoetin alfa). The biosimilar, called Cresp, has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy, Dr. Reddy's announced Aug. 9

You may also be interested in...



India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim

With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.

India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim

With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.

With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim

MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel